Lack of Toxicity With Long-term Isavuconazole Use in Patients With Hematologic Malignancy

Abstract

Prolonged courses of isavuconazole (ISA) are increasingly utilized in immunocompromised patients. Toxicities have been reported with long-term use of the other triazoles. We report the first real-life tolerability data in 50 patients with hematologic malignancy receiving ≥6 months of ISA. ISA was well tolerated in our ill patient population.

Keywords: hematologic malignancy; invasive mold infections; isavuconazole; toxicity.